5 Best Biotech Stocks To Invest In Right Now

5 Best Biotech Stocks To Invest In Right Now: Merck & Company Inc.(MRK)

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company?s Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, diabetes and obesity, infectious diseases, neurosciences and ophthalmology, oncology, vaccines, and women's health and endocrine. This segment also offers human health vaccines, such as preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products. This segment offers antibiotics, anti-inflammatory products, vaccines, products for the treatment of fertility disorders, and parasiticides for cattle, swine, horses, poultry, dogs, cats, salmons, and fish. The Consumer Care segment develops, manufac tures, and markets over-the-counter, foot care, and sun care products. Its over-the-counter product line includes non-drowsy antihistamines; treatment for occasional constipation; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant spray; and treatment for frequent heartburn. This segment?s foot care products comprise topical antifungal, and foot and sneaker odor/wetness products; and sun care products include sun care lotions, sprays and dry oils; and sunburn relief products. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, and managed health care providers, as well as food chain and mass merchandiser outlets in the United States and Canada. Merck & Co., Inc. was founded in 1891 and is headquartered in Whitehouse S! tation, New Jersey.

Advisors' Opinion:

• [By Brian Orelli]

  Gilead should gain FDA approval shortly for its all-oral HPV treatment that combines Sovaldi with another drug. While the statement makes it sound like there won't be a price increase, that's not really the case. Currently, many people infected with HPV have to take Sovaldi and either Merck's (NYSE: MRK  ) Pegintron or Roche's Pegasys. The plan seems to be to price the Sovaldi combination at the current price of Sovaldi plus the price of the companion drug.

• [By vl2014]

  Merck (MRK) led the Dog pack for the month of August with a gain of 5.9%. The New Jersey-based drugmaker reported second-quarter earnings that were comfortably ahead of our expectations, thanks to better-than-expected performance on the top line and continued tight cost controls. Regarding the former, although worldwide revenues were down 1% year over year, to $10.9 billion, this was $300 million ahead of our estimate, as stronger gains in the company's core franchises helped to mitigate generic competition and declines in Hepatitis-C drugs.

source from Top Stocks For 2015:http://www.topstocksblog.com/5-best-biotech-stocks-to-invest-in-right-now-2.html